The Future of Stem Cell Transplantation: Insights from Dr. Kevin McNerney
In an era where medical science is rapidly transforming lives, stem cell transplantation stands at the forefront of innovative treatment. At the Bone Marrow Transplant and Gene Therapy Congress in Abu Dhabi, Dr. Kevin McNerney from the Ann & Robert H. Lurie Children’s Hospital in Chicago shares groundbreaking updates and real-world insights into this life-saving […]
Celularity and BlueSphere Bio Collaborate on Cell Therapy Manufacturing
Celularity Inc., a cellular medicine company, has entered into a collaboration agreement with BlueSphere Bio (BSB).? Celularity will leverage its manufacturing capabilities to produce BSB’s T cell receptor (TCR) T cell therapies.? This partnership will focus on manufacturing and quality control at Celularity’s New Jersey facility for BSB’s therapies, including a treatment for Acute Myelogenous […]
Longeveron: WHO Approves “Laromestrocel” for Lomecel-Bâ„¢ Stem Cell Therapy
Longeveron Inc. announced that the World Health Organization (WHO) has approved the International Non-proprietary Name (INN) “laromestrocel” for their cellular therapy Lomecel-Bâ„¢? Lomecel-Bâ„¢ is being evaluated as a treatment for Alzheimer?s disease and hypoplastic left heart syndrome (HLHS).? It is a proprietary product made from medicinal signaling cells and has received FDA designations such as […]
NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery
The New York Stem Cell Foundation Research Institute (NYSCF) and Janssen Research & Development, a Johnson & Johnson company, have partnered to accelerate the development of precision medicines for neurodegenerative diseases. NYSCF’s AI-powered platform, using automated stem cell systems, will be leveraged to identify new drug targets and therapies. This collaboration combines NYSCF’s expertise in stem cell […]
BioCentriq Expands Cell Therapy Manufacturing
This exciting news in the cell therapy sector could revolutionize how quickly life-changing therapies reach patients. BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), is set to expand its operations and establish a cutting-edge cell therapy manufacturing facility in Princeton, New Jersey. This facility will become BioCentriq’s new headquarters, marking a significant […]
FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy
StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024. REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood. The company is also exploring other applications […]
Revolutionary Stem Cell Therapy Shows Promising Improvements for Children with Autism
In a groundbreaking development in stem cell research, families of children with autism are seeing life-changing transformations. Highlighted in a recent Fox 17 News report, parents share heartfelt stories of their children’s behavioral and developmental milestones achieved through stem cell therapy. From improved social interactions to newfound verbal abilities, the therapy offered by the Kellum […]
BioRestorative Therapies Expands Stem Cell Research with New York State License
In a significant advancement for regenerative medicine, BioRestorative Therapies, Inc. has secured a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic (non-autologous) donor tissue material, including stem cells, for medical research. This expansion builds upon their previous authorization, which was limited to autologous (self-donated) mesenchymal stem cells. This new […]
Pioneering Stem Cell Therapy Shows Promise in Alzheimer’s Treatment: Regeneration Biomedical Releases First Cohort Results
In a breakthrough for Alzheimer’s disease research, Regeneration Biomedical, Inc. recently presented promising findings from a Phase I clinical trial that delivers stem cell therapy directly into the brains of patients. Utilizing Wnt-activated, autologous, expanded, adipose-derived stem cells (RB-ADSCs), the therapy is designed to potentially slow or reverse the progression of Alzheimer’s. These specialized stem […]
BioCardia Completes Phase III Clinical Trial of Autologous Stem Cell Therapy for Ischemic Heart Failure
BioCardia, Inc., a leader in cellular therapies for cardiovascular diseases, has announced the completion of its pivotal Phase III trial for CardiAMP®, an autologous cell therapy designed to treat ischemic heart failure with reduced ejection fraction (HFrEF). This milestone marks the last patient follow-up in the double-blind, placebo-controlled trial, which aims to assess the safety […]